AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

That is the conclusion of the Advance-HTN study reported at the American College of Cardiology (ACC) meeting, which found ...

The awards ceremony will be held at The Brewery, London, on Thursday 11 th September 2025 where we will host 500+ guests from ...

At Reuters Pharma USA in Philadelphia, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US ...

Cell and gene therapies offers transformative benefits to patients, including revolutionary treatment potential for cancer, ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

The Dermatology Drug Development Summit Europe returns for its 6th year as the premier industry forum dedicated to advancing ...

Lilly and Novartis have collectively pledged almost $3 billion to their partnerships with Isomorphic signed last year, which ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

Celebrating its 10th anniversary, the Microbiome Movement USA Summit will reunite the community with perspectives from 140+ ...

Lilly said it is planning to request a re-examination of the CHMP's appraisal of Kisunla, pointing out that the drug has ...